Skip to main content
Anil Tarachandani

Anil Tarachandani

Vice President and Head of Translational Medicine, Verge Genomics
Dr. Anil Tarachandani joins Verge Genomics from Pfizer where he led multifunctional teams to bring novel, specific and quantitative endpoints to clinical research while interacting with FDA for their recognition and endorsement. His experience in the biopharmaceutical industry includes small, medium, and large companies in multiple therapeutic areas. In a decade-long career at Merck, he grew from a research scientist in the immunology group to leading a cardiovascular sub team that helped bring cholesterol modulating drugs to market. Anil’s leadership in the use of innovative high throughput automated technologies, led to a global business development role with dedicated budget for bringing innovation to Merck. Anil’s passion is to evaluate drug efficacy and he founded an innovative digital diagnostics company to develop POWERjar, a simple yet powerful device to measure changes in muscle strength. He joined Biogen with a goal of combining such novel technologies, with others in the Experimental Medicine group, to bring precise, quantitative, and decision-making assessments to late-stage programs. Anil’s PhD is in oncology with post-doctoral training at the University of Massachusetts. He spent the initial years of his career in academia at Carnegie Mellon developing automated, fast, AI / ML based methods of acquiring and analyzing thousands of microscopic images to determine drug efficacy and identify drugs that showed unique characteristics.